KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeTax ProvisionsTax Rate
Others
Ratios

Bristol Myers Squibb (BMY) Other Operating Expenses (2016 - 2025)

Historic Other Operating Expenses for Bristol Myers Squibb (BMY) over the last 17 years, with Q4 2025 value amounting to $6.3 billion.

  • Bristol Myers Squibb's Other Operating Expenses fell 840.64% to $6.3 billion in Q4 2025 from the same period last year, while for Dec 2025 it was $21.6 billion, marking a year-over-year decrease of 4165.9%. This contributed to the annual value of $21.6 billion for FY2025, which is 4165.9% down from last year.
  • Per Bristol Myers Squibb's latest filing, its Other Operating Expenses stood at $6.3 billion for Q4 2025, which was down 840.64% from $4.8 billion recorded in Q3 2025.
  • Over the past 5 years, Bristol Myers Squibb's Other Operating Expenses peaked at $18.3 billion during Q1 2024, and registered a low of $4.4 billion during Q1 2025.
  • Its 5-year average for Other Operating Expenses is $6.0 billion, with a median of $5.3 billion in 2021.
  • In the last 5 years, Bristol Myers Squibb's Other Operating Expenses surged by 30854.15% in 2024 and then plummeted by 7604.13% in 2025.
  • Bristol Myers Squibb's Other Operating Expenses (Quarter) stood at $5.3 billion in 2021, then decreased by 9.21% to $4.8 billion in 2022, then rose by 10.08% to $5.3 billion in 2023, then skyrocketed by 30.24% to $6.8 billion in 2024, then dropped by 8.41% to $6.3 billion in 2025.
  • Its Other Operating Expenses was $6.3 billion in Q4 2025, compared to $4.8 billion in Q3 2025 and $6.2 billion in Q2 2025.